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Abstract. 
 
DEK is an 
 
z
 
45-kD phosphoprotein that is 
fused to the nucleoporin CAN as a result of a (6;9) 
chromosomal translocation in a subset of acute myeloid 
leukemias (AMLs). It has also been identiﬁed as an au-
toimmune antigen in juvenile rheumatoid arthritis and 
other rheumatic diseases. Despite the association of 
DEK with several human diseases, its function is not 
known. In this study, we demonstrate that DEK, to-
gether with SR proteins, associates with the SRm160 
splicing coactivator in vitro. DEK is recruited to splic-
ing factor-containing nuclear speckles upon concentra-
tion of SRm160 in these structures, indicating that DEK 
and SRm160 associate in vivo. We further demonstrate 
that DEK associates with splicing complexes through 
interactions mediated by SR proteins. Signiﬁcantly, 
DEK remains bound to the exon-product RNA after 
splicing, and this association requires the prior forma-
tion of a spliceosome. Thus, DEK is a candidate factor 
for controlling postsplicing steps in gene expression 
that are inﬂuenced by the prior removal of an intron 
from pre-mRNA.
Key words: SR proteins • spliceosome • mRNP • 
mRNA • transport
 
Introduction
 
Increasing evidence suggests that different processes in
gene expression communicate and are functionally coordi-
nated with each other. For example, it has been demon-
strated that transcription factors can influence the process-
ing of a pre-mRNA. In this case, splicing and selection of
polyadenylation sites can be influenced by promoter se-
quences that drive transcription by RNA polymerase II
(pol II)
 
1
 
 (Leroy et al., 1991; Cramer et al., 1997, 1999).
Moreover, the COOH-terminal domain (CTD) of pol II is
important for efficient capping, splicing, and 3
 
9
 
 end cleav-
age of nascent pre-mRNA (Cho et al., 1997; McCracken
et al., 1997a,b). Splicing and 3
 
9
 
 end formation also influ-
ence each other, and interactions between these processes
are important for the definition of terminal exons in pre-
mRNA (Niwa and Berget, 1991; Wassarman and Steitz,
1993; Nesic and Maquat, 1994; Gunderson et al., 1997;
Bauren et al., 1998; Lou et al., 1998; Vagner et al., 2000).
Recently, it was demonstrated that the transport of mRNA
from the nucleus to the cytoplasm is promoted by prior
splicing, since mRNAs that had not been generated by
splicing were inefficiently transported (Luo and Reed,
1999). Currently, it is not understood how individual steps
in the gene expression pathway communicate with each
other, although several lines of evidence indicate that pro-
teins containing domains rich in alternating arginine and
serine residues (RS domains), including several splicing
factors, may be important for the coupling of splicing to
other steps in pre-mRNA metabolism (reviewed in Fu,
1995; Corden and Patturajan, 1997; Blencowe et al., 1999).
Pre-mRNA splicing involves the step-wise assembly of
large RNA-protein complexes, termed spliceosomes (re-
viewed in Kramer, 1996; Reed and Palandjian, 1997;
Burge et al., 1999). The major spliceosome contains four
small nuclear ribonucleoprotein particles (snRNPs: U1,
U2, U4/U6, and U5) and many non-snRNP splicing fac-
tors. A large number of non-snRNP splicing factors con-
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Abbreviations used in this paper:
 
 AML, acute myeloid leukemia; CTD,
COOH-terminal domain; ESE, exonic splicing enhancer; EV, epidermo-
dysplasia verruciformis; hnRNP, heteronucleoriboprotein; HPV, human
papillomavirus; pets, peri-ets; rAb, rabbit polyclonal antibody; RNA pol
II, RNA polymerase II; RS domain, domain rich in alternating arginine
and serine residues; snRNPs, small nuclear ribonucleoprotein particles;
SR protein, serine/arginine-repeat protein. 
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tain RS domains. Among these are members of the SR
family, which share a common domain structure consisting
of one or two NH
 
2
 
-terminal RNA recognition motifs and a
phosphorylated COOH-terminal RS domain (Fu, 1995;
Manley and Tacke, 1996; Valcarcel and Green, 1996).
Other RS domain-containing non-snRNP splicing factors
have a distinct structural organization and are referred to
as SR-related proteins (Fu, 1995; Blencowe et al., 1999).
These include factors such as the alternative splicing regu-
lators Tra, Tra2, and SWAP, as well as the subunits of the
SRm160/300 splicing coactivator. The RS domains of SR
family and SR-related proteins form interactions with
each other and with snRNP-associated proteins that con-
tain RS domains, and increasing evidence indicates that
these interactions are critical for the formation of net-
works of interactions that promote splice site recognition
across both intron and exon sequences.
Several SR-related proteins and interacting factors have
been identified recently that are associated with transcrip-
tion and 3
 
9
 
 end processing. These include the E2 protein of
the epidermodysplasia verruciformis (EV)-associated hu-
man papillomavirus (HPV), which binds to promoter se-
quences and is important for the transcriptional regulation
of viral genes. The EV-HPV E2 protein contains an RS
hinge domain that interacts with serine/arginine-repeat
proteins (SR proteins) involved in splicing, and appears
to promote the splicing of pre-mRNAs transcribed from
promoters activated specifically by the EV-HPV E2 pro-
tein (Lai et al., 1999). A class of SR-related proteins, re-
ferred to as SCAFs (SR-like CTD-associated factors), has
been identified that preferentially bind to the hyperphos-
phorylated CTD of RNA pol II, which is the form of the
CTD associated with elongating transcription complexes
(Yuryev et al., 1996; Bourquin et al., 1997; Tanner et al.,
1997; Patturajan et al., 1998). An SR-related protein
(PCG-1) has been identified that functions as a transcrip-
tional coactivator of nuclear receptors, which is implicated
in adaptive thermogenesis in mice (Puigserver et al., 1998).
Another new transcriptional coactivator (p52) has been
identified that lacks an RS domain, but interacts with the
SR family protein ASF/SF2, as well as with several tran-
scription factors (Ge et al., 1998). The 68-kD subunit of
the mammalian cleavage factor (CFIm), which functions
in the 3
 
9
 
 end of processing transcripts, was recently iso-
lated and found to contain an RS domain (Ruegsegger et
al., 1998). These studies indicate that a variety of proteins
containing RS domains are candidates for factors that co-
ordinate different steps during the synthesis and process-
ing of pre-mRNA.
SR family and SR-related proteins have been implicated
in steps downstream of pre-mRNA splicing. Several SR
proteins, including SRm160/300 and ASF/SF2, remain bound
preferentially to the ligated exon-product, but not the in-
tron-lariat product of the splicing reaction, which associ-
ates with snRNPs (Blencowe et al., 1998, 2000; Hanamura
et al., 1998). A subset of SR family proteins shuttle be-
tween the nucleus and the cytoplasm, suggesting that they
could function in the nuclear–cytoplasmic transport of
mRNA (Cáceres et al., 1998). Recently, it was observed
that complexes formed on exon-product RNAs generated
by splicing are larger and more efficiently transported to
the cytoplasm than complexes formed on the same RNAs
 
that have not been through splicing (Luo and Reed, 1999).
This observation suggests that there are factors that are
targeted for association with mRNA by the splicing ma-
chinery, and may relate to numerous earlier observations
that introns are important for the efficient expression of
genes.
In the present study, we have identified the oncoprotein
DEK as a splicing complex component that remains asso-
ciated with spliced exons dependent on prior splicing of
pre-mRNA. Furthermore, we show that the association of
DEK with splicing complexes is mediated by specific inter-
actions involving SR proteins. DEK is an 
 
z
 
45-kD phos-
phoprotein that was previously identified in the context of
several human diseases. It was first isolated as part of a fu-
sion that arises in a subtype of acute myeloid leukemias
(AMLs) involving (6;9) chromosomal translocations (von
Lindern et al., 1992). These translocations occur within in-
tron sequences of the genes encoding 
 
dek
 
 and the nucleo-
porin 
 
can
 
, and result in the expression of an in-frame chi-
mera encoding the majority of DEK fused NH
 
2
 
-terminally
to the COOH-terminal two-thirds of CAN. DEK was later
identified as an autoimmune antigen in patients with pau-
ciarticular onset juvenile rheumatoid arthritis, systemic lu-
pus erythematosus, and other autoimmune diseases (Szer
et al., 1994; Dong et al., 1998; Wichmann et al., 2000). In
another study, it was reported that DEK binds to a TG-
rich element, the pets (peri-ets) site, which is adjacent to
two binding sites of the ets family member, Elf-1, in the
HIV-2 enhancer, which mediates enhancer activation by a
number of signaling processes (Fu et al., 1997). However,
the specificity and functional significance of the binding of
DEK to the pets site is not known. The results in the
present study indicate that DEK may have one or more
functions in association with pre-mRNA processing. In
particular, the results identify DEK as one of the first fac-
tors that associates with mRNA in a splicing-dependent
manner, indicating that it could function to coordinate
splicing with one or more subsequent steps in gene expres-
sion.
 
Materials and Methods
 
Protein Purification 
 
Fractionation of p130.  
 
Fractionation was initiated with 
 
z
 
200 ml of HeLa
nuclear extract (
 
z
 
10 mg/ml) that was prepared as described by Dignam
et al. (1983), except that the final dialysis was against a modified buffer D
containing 10% glycerol (20 mM Hepes, pH 7.9, 10% glycerol, 0.2 mM
EDTA, 0.05% NP-40, 0.5 mM DTT). The dialyzed nuclear extract was
chromatographed over a poly-U Sepharose column as described by
Zamore and Green (1989). The flow-through fraction was chromato-
graphed over a phosphocellulose column as described by Samuels et al.
(1982). p130 and other SR proteins were detected entirely in the 1.0 M salt
elution. The 1.0 M salt elution from the phosphocellulose column was dia-
lyzed against SR-dialysis buffer (SRDB; 65 mM KCl, 15 mM NaCl, 10 mM
Hepes, pH 7.6, 1 mM EDTA, 2 mM DTT, 5 mM KF, 5 mM 
 
b
 
-glycero-
phosphate, 0.2 mM Pefabloc [Boehringer]; modified from Zahler et al.,
1992). Precipitate formed during dialysis, which contained the majority of
SRm160, but not p130, was removed by centrifugation. The cleared frac-
tion was incubated for 15 min at 30
 
8
 
C in the presence of 1.5 mM ATP and
5 mM creatine-PO
 
4
 
 to regenerate phosphoepitopes detected by mAb-104,
and was then recentrifuged to remove further precipitate. The superna-
tant fraction was mixed with an equal volume of SRDB containing 6 M
urea and then chromatographed over a Q-Sepharose column preequili-
brated with 3 M urea-SRDB. Proteins were step-eluted with increasing
concentrations of KCl in the 3 M urea-SRDB buffer. A sample of the 
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0.3 M step elution (Q-Sepharose-0.3 M, Q-0.3M), which contained the ma-
jority of p130 and other SR proteins detected by immunoblotting with
mAb-104, was precipitated with TCA in the presence of deoxycholate.
The TCA pellet was washed with ice-cold acetone, dried briefly, and re-
suspended in Laemmli loading buffer. The sample was separated on a
12% SDS polyacrylamide gel and detected by Coomassie staining (Fig. 1
C). The p130 doublet and other visible bands were excised, digested in situ
with trypsin, and analyzed by MALDI-TOF mass spectroscopy using a
PerSeptive Biosystems (model DE-STR) mass spectrometer. Details of
sample preparation can be obtained from borealis biosciences, inc.
 
Purification of SR Family Proteins.  
 
Purification of the set of 6 defined
SR proteins was performed essentially as described by Zahler et al.
(1992).
 
Antibodies
 
The following antibodies were used in this study: murine mAb-104 (Roth
et al., 1990); mAb-B1C8 (Blencowe et al., 1994; Wan et al., 1994;
Matritech); mAb-B3 (Mortillaro et al., 1996); mAb-NM4 (Blencowe et al.,
1995; Matritech); mAb anti-Flag (VWR-Scientific); rabbit polyclonal anti-
body (rAb)-DEK (Fornerod et al., 1995); and rAb-SRm300 (Blencowe et
al., 2000).
 
Nuclear and Cytoplasmic Extracts
 
HeLa nuclear and cytoplasmic S100 extracts were prepared essentially as
described by Dignam et al. (1983). Nuclear extract depleted of DEK pro-
tein was prepared by the same procedure as described for SRm160/300 in
Blencowe et al. (1998).
 
Splicing and Immunoprecipitation Assays
 
Immunoprecipitation of SR protein complexes in the presence and ab-
sence of ribonuclease (Fig. 2) was performed as described by Eldridge et al.
(1999). Immunoprecipitation of splicing complexes was performed as de-
scribed in Blencowe et al. (1994). Splicing assays using the PIP85A pre-
mRNA were carried out as described by Blencowe et al. (1998). Splicing
assays using the dsx(GAA)
 
6
 
 pre-mRNA were performed as described by
Eldridge et al. (1999). The splicing reactions containing S100 extract (see
Fig. 5) were performed in a total volume of 15 
 
m
 
l and were supplemented
with 
 
z
 
3 
 
m
 
g of purified SR family proteins where indicated. The splicing
reactions containing PIP85A pre-mRNA were analyzed on 15% denatur-
ing polyacrylamide gels; doublesex (dsx)
 
 
 
splicing reactions were analyzed
on 7 or 10% denaturing polyacrylamide gels.
 
Affinity Selection of Splicing Complexes 
 
Affinity selection of splicing complexes assembled on biotinylated dsx
pre-mRNAs was performed essentially as described in Li and Blencowe
(1999).
 
SDS-PAGE and Immunoblot Analysis
 
SDS-PAGE and immunoblots were performed essentially as described by
Harlow and Lane (1988). Immunoblots in Figs. 1, 4, and 5 were developed
using a secondary antibody conjugated to HRP and chemiluminescence
detection (NEN Life Science Products), as per the manufacturer’s instruc-
tions.
 
Immunocytochemistry
 
HeLa cells were immunolabeled as described by Blencowe et al. (1998).
The samples were examined and recorded using a Leica-SP confocal mi-
croscope.
 
Results
 
DEK Copurifies with SR Proteins
 
To identify new SR-related proteins and associated factors
that function in pre-mRNA processing, we have fraction-
ated HeLa cell nuclear extract for proteins that react with
mAb-104, which binds to a phosphoepitope located within
the RS domains of many SR proteins (Roth et al., 1990).
 
We initially focused our attention on an antigen of 130 kD
(p130), since an SR protein of this size recognized by
mAb-104 had not been isolated previously. Using immu-
noblotting with mAb-104 to monitor purification, we frac-
tionated HeLa nuclear extract for p130 by the scheme
shown in Fig. 1 A (see Materials and Methods). The 0.3 M
KCl elution step from the final (Q-Sepharose) column
yielded subfractions that were highly enriched in a doublet
of mAb-104 antigens that migrated at 130 kD, as well as
antigens detected by this antibody corresponding in size to
previously identified SR family proteins of 
 
z
 
75, 55, and
30 kD. The levels of the p130 doublet detected by immu-
noblotting with mAb-104 correlated precisely with the lev-
els of a doublet of polypeptides of 130 kD detected in the
same subfractions by Coomassie staining, indicating that
one or both of the latter species correspond to p130 (data
not shown). Fig. 1 B shows an immunoblot of the peak
Q-0.3M fraction probed with mAb-104, and Fig. 1 C shows a
corresponding Coomassie-stained gel. Besides the 130-kD
doublet, relatively abundant polypeptides of 120, 50, 35,
20, and 17 kD were detected in the fraction by Coomassie
staining (indicated by arrows in Fig. 1 C).
To determine the identity of the p130 proteins, as well as
the other proteins in the Q-0.3M fraction, the bands indi-
cated in Fig. 1 C were excised, digested with trypsin in situ,
and the released peptides were analyzed by MALDI-TOF
mass spectroscopy. The masses of peptides from each pro-
tein were used to search for corresponding peptide masses
in conceptually translated sequences from the databases.
Figure 1. DEK copurifies with SR proteins. A, Fractionation
scheme for a 130-kD antigen recognized by mAb-104 (p130;
see Materials and Methods). B, mAb-104 immunoblot of the
Q–Sepharose 0.3-M (Q-0.3M) fraction obtained by the scheme in
A. SR proteins of z75, 50, and 30 kD detected by mAb-104 copu-
rify with p130. Size markers are indicated in kD. C, Coomassie-
stained SDS polyacrylamide gel of the Q-0.3M fraction. The
identities of the abundant polypeptides, migrating at 130, 50, and
34 kD, were identified by MALDI-TOF mass spectroscopy as
Hel117, DEK, and SC35, respectively. Size markers are indicated
in kD. 
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Close matches were obtained between peptides from both
polypeptides in the p130 doublet, identifying these as
Hel117. The 
 
z
 
50- and 35-kD proteins were identified as
DEK and SC35, respectively (data not shown). Consistent
with its reactivity with mAb-104, Hel117 is a previously re-
ported protein of unknown function that contains an RS
domain (Sukegawa and Blobel, 1995), and SC35 is a previ-
ously characterized member of the SR family of splicing
factors (Fu and Maniatis, 1992). Hel117 contains other do-
main features found in splicing factors, including a DEAD-
box and associated motifs shared between proteins with
dsRNA unwinding and/or nucleic acid-dependent ATPase
activity. It also contains a separate domain that is homolo-
gous to a region within the yeast splicing factor, PRP5.
Consistent with a possible role in splicing, Hel117 was pre-
viously localized to nuclear speckle domains enriched in
pre-mRNA splicing factors (Sukegawa and Blobel, 1995),
and we have found that it associates with other SR pro-
teins and splicing complexes in vitro (unpublished obser-
vations). Interestingly, DEK is a multidisease-associated
phosphoprotein of unknown function that was originally
identified as an in-frame fusion partner with the nucleo-
porin CAN, generated by a specific (6;9) chromosomal
translocation in a subset of AML (von Lindern et al., 1992;
see Introduction). It contains several regions rich in
charged residues, including an NH
 
2
 
-terminal acidic do-
main similar to those found in transcriptional activator
proteins. A comparison of the DEK amino acid sequence
against sequences in the databases identified homologous
sequences within predicted open reading frames of ze-
brafish, fly, and plant expressed sequence tag cDNAs, but
did not reveal a significant homology with any character-
ized protein (data not shown).
The 55- and 75-kD SR proteins that were detected in
the Q-0.3M fraction by immunoblotting with mAb-104
were not detected in the Coomassie stained gel in Fig. 1 C
because these proteins are lower in abundance than the
polypeptides that were analyzed. The detection of these
antigens and the identification by mass spectroscopy of
two RS domain proteins in the Q-0.3M fraction, Hel117
and SC35, demonstrates that the fractionation scheme in
Fig. 1 A enriches for SR proteins associated with pre-
mRNA processing. The cofractionation of DEK with
several SR proteins suggested that it either has similar
chromatographic properties as these factors, or, more in-
terestingly, that it may be associated with one or more SR
proteins in a complex. To distinguish between these possi-
bilities, we next addressed whether DEK interacts with SR
proteins.
 
DEK Associates with SR Proteins In Vitro
 
Immunoprecipitates were collected from HeLa nuclear
extract using an mAb specific for the SRm160 subunit of
the SRm160/300 splicing coactivator (mAb-B1C8; Blen-
cowe et al., 1994; Wan et al., 1994). This antibody immu-
noprecipitates SRm160/300 efficiently and, in the presence
of low salt concentrations, coimmunoprecipitates several
proteins that contain RS domains, including Hel117,
hTra2beta (a human homologue of the 
 
Drosophila mela-
nogaster 
 
alternative splicing factor, Tra2) and SR family
proteins (Eldridge et al., 1999; and our unpublished data).
To determine whether DEK associates with one or more
of these SR proteins, the immunoprecipitates were immu-
noblotted with an antibody that is highly specific for DEK
(rAb-DEK; Fig. 2; Fornerod et al., 1995). In total HeLa
nuclear extract, rAb-DEK detected a major band of 
 
z
 
50-
55 kD and a minor band of 
 
z
 
40 kD. The major band cor-
responds in size to a form of DEK that is posttranslation-
ally modified by phosphorylation, whereas the minor band
is thought to correspond to a cleavage product of DEK
(Fig. 2, lanes 1 and 2; Fornerod et al., 1995). The specificity
of rAb-DEK for DEK has been confirmed by immuno-
blotting whole cell extracts from DEK
 
1
 
/
 
1
 
 and DEK
 
2
 
/
 
2
 
mice. Both bands are detected by rAb-DEK in 
 
1
 
/
 
1
 
 ex-
tracts, but neither band, nor any other antigen, is detected
in the 
 
2
 
/
 
2
 
 extracts (data not shown).
mAb-B1C8, but not a control mAb of the same isotype
that is specific for a hyperphosphorylated form of the RNA
pol II large subunit (mAb-B3; Mortillaro et al., 1996), spe-
cifically coimmunoprecipitated DEK (Fig. 2, compare lane
5 with 4). This coimmunoprecipitation was not reduced by
extensive pretreatment of nuclear extract with RNAse
(Fig. 2, compare lanes 5 and 8), indicating that DEK asso-
ciates with one or more SR proteins through protein–pro-
tein interactions and is not tethered to these proteins by
RNA. Thus, consistent with the cofractionation of DEK
with SR proteins (Fig. 1), the results indicate that DEK is
associated with one or more SR proteins that function in
pre-mRNA splicing. To extend these observations, we
next determined whether or not DEK associates with SR
proteins during the formation of pre-mRNA splicing com-
plexes (Fig. 3).
 
Association of DEK with Splicing Complexes
 
Remarkably, rAb-DEK immunoprecipitated splicing com-
plexes assembled on a constitutively spliced pre-mRNA
derived from adenovirus PIP85A (Fig. 3 A). Similar to a
Figure 2. DEK associates with SR proteins. Immunoprecipitates
were collected from HeLa nuclear extract preincubated with
(lanes 6–8) or without (lanes 3–5) RNase using the following an-
tibodies: an mAb specific for the SRm160 subunit of the
SRm160/300 splicing coactivator (mAb-B1C8, lanes 5 and 8); an
mAb specific for hyperphosphorylated RNA pol II large subunit
(mAb-B3, lanes 4 and 7); and a control antiserum (rAb anti-
mouse, lanes 3 and 6). The immunoprecipitates were separated
on an SDS polyacrylamide gel and immunoblotted with rAb-
DEK. The corresponding total HeLa nuclear extracts treated
without or with RNase, corresponding to 10% of the amount of
nuclear extract used in each immunoprecipitation, are separated
in lanes 1 and 2, respectively. 
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polyclonal antibody specific for SRm300 (rAb-SRm300;
Blencowe et al., 2000), which was used as a positive con-
trol for immunoprecipitation, rAb-DEK efficiently im-
munoprecipitated splicing complexes containing exon
sequences (pre-mRNA, splicing intermediates, and exon-
product RNA) and, to a lesser degree, the complex con-
taining the lariat product of the splicing reaction (Fig. 3 A,
lanes 3 and 4). The immunoprecipitation of splicing com-
plexes by rAb-DEK was specific since neither preimmune
serum, nor a saturating amount of a control immune se-
rum bound to protein A beads, immunoprecipitated splic-
ing complexes (Fig. 3 A, lane 2, and data not shown; see
also Eldridge et al., 1999). These results provide evidence
that DEK associates with splicing complexes through both
steps of the splicing reaction. Moreover, the similar profile
of immunoprecipitation of splicing complexes observed
between rAb-DEK and rAb-SRm300 is consistent with
the data in Fig. 2, indicating that DEK and SRm160/300
associate with each other (see below).
To investigate the specificity of the interaction of DEK
with splicing complexes in more detail, we next deter-
mined whether it can associate with a distinct pre-mRNA,
and also whether it can associate with an RNA that is not a
splicing substrate. To test for these properties, rAb-DEK
was assayed for its ability to immunoprecipitate splicing
complexes assembled on a pre-mRNA derived from exons
3 and 4 of the 
 
dsx 
 
gene of 
 
Drosophila
 
, and also the corre-
sponding antisense RNA, which does not assemble func-
tional splicing complexes (Fig. 3 B). Wild-type 
 
dsx
 
 pre-
mRNA contains a suboptimal 3
 
9
 
 splice site upstream of
exon 4. In 
 
Drosophila
 
, efficient recognition of this splice
site and subsequent intron removal requires the assembly
on a specialized exonic splicing enhancer (ESE) within
exon 4 of a multisubunit complex that contains the RS do-
main splicing factors Tra, Tra2, and the SR family protein
RBP-1 (SRp20; Inoue et al., 1992; Tian and Maniatis,
1993, 1994). The substrate used in the present study con-
tains a typical purine-rich mammalian ESE consisting of
six GAA repeats in place of the dsx ESE (Yeakley et al.,
1996). This 6xGAA ESE promotes the stable association
of hTra2
 
b
 
, several SR family proteins, and SRm160/300
with the dsx pre-mRNA, and is required for efficient splic-
ing of this substrate in HeLa nuclear extracts (see below;
Yeakley et al., 1996; Eldridge et al., 1999; Li and Blen-
cowe, 1999). The results in Fig. 3 B demonstrate that rAb-
DEK, like rAb-SRm300, efficiently immunoprecipitated
splicing complexes assembled on the dsx(GAA)
 
6
 
 pre-
mRNA (lanes 4 and 5), but only weakly immunoprecipi-
tated the antisense RNA (lanes 7 and 8). These results in-
dicate that DEK may be a general component of splicing
complexes, but that it does not associate stably with an
RNA that does not form functional splicing complexes.
Given the association of DEK with SR proteins, includ-
ing SRm160/300 observed in Fig. 2, and the similar profiles
of immunoprecipitation of splicing complexes observed
between antibodies to both DEK and SRm300 (Fig. 3, A
and B), we next determined whether or not SR proteins
mediate the association of DEK with splicing complexes.
To test if this is the case, we initially compared the ability
of DEK to associate with splicing complexes assembled
on the dsx(GAA)
 
6
 
 pre-mRNA versus the same substrate
lacking an ESE (dsx
 
D
 
E; Fig. 3 C). Previously, we have
Figure 3. Association of
DEK with splicing com-
plexes. A, Immunoprecipita-
tion of splicing complexes
with rAb-DEK from reac-
tions incubated for 1 h con-
taining PIP85A pre-mRNA.
RNA recovered after immu-
noprecipitation (lanes 2–4)
and RNA recovered directly
from a parallel splicing reac-
tion (lane 1), was loaded on a
15% denaturing polyacryl-
amide urea gel. RNA loaded
in lane 1 represents 25% of
the total amount recovered,
whereas RNA loaded in
lanes 2–4 from each immuno-
precipitation represents 50%
of the total amounts recov-
ered. Immunoprecipitations were performed with preimmune serum (lane 2), rAb-DEK (lane 3), and rAb-SRm300 as a positive control
(lane 4). B, Complexes were immunoprecipitated from splicing reactions incubated for 45 min containing either a dsx(GAA)6 pre-
mRNA (lanes 1, and 3–5) or the corresponding antisense RNA (lanes 2, and 6–8). RNA recovered after immunoprecipitation (lanes
3–8) and RNA recovered directly from parallel splicing reactions (lanes 1 and 2) was loaded on a 10% denaturing polyacrylamide urea
gel. The antibodies used for immunoprecipitation and the relative amounts of RNA loaded from the total and immunoprecipitation
samples are as described in A. C, Association of DEK with a two-exon dsx pre-mRNA is promoted by a 6xGAA ESE sequence in the
39 exon. Immunoprecipitation was performed from splicing reactions incubated for 45 min containing dsx pre-mRNA lacking an
ESE (dsxDE; lanes 1, and 3–5) or from reactions containing dsx pre-mRNA with the 6xGAA ESE (dsx(GAA)6; lanes 2, and 6–8).
RNA recovered after immunoprecipitation (lanes 3–8) and RNA recovered directly from a parallel splicing reactions (lanes 1 and 2)
was loaded on a 10% denaturing polyacrylamide urea gel. Antibodies used for immunoprecipitation and the relative amounts of RNA
loaded from the total and immunoprecipitation samples are as described in A. 
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shown that U1 snRNP and U2AF-65 kD bind equally to
these substrates but, as mentioned above, SRm160/300,
Tra2beta, and SR family proteins only associate stably
with the dsx(GAA)
 
6
 
 pre-mRNA (Eldridge et al., 1999; Li
and Blencowe, 1999). Similar to rAb-SRm300, rAb-DEK
efficiently immunoprecipitated splicing complexes assem-
bled on the dsx(GAA)
 
6
 
 substrate, but inefficiently immu-
noprecipitated complexes assembled on the dsx
 
D
 
E sub-
strate (Fig. 3 C, compare lanes 7 and 8 with 4 and 5). The
data demonstrate that a 6xGAA ESE results in a signifi-
cant increase in the association of both DEK and SRm300
with the dsx pre-mRNA, again consistent with the data in
Fig. 2 indicating that these components interact. As be-
fore, the ability of rAb-DEK and rAb-SRm300 to immu-
noprecipitate splicing complexes on the dsx substrates was
not due to nonspecific interactions since neither preim-
mune serum, nor high levels of control immune sera, im-
munoprecipitated significant levels of these complexes (Fig.
3 C, lanes 3 and 6; see also Eldridge et al., 1999).
To confirm that the different levels of immunoprecipita-
tion of the dsx
 
D
 
E and dsx(GAA)
 
6
 
 splicing complexes by
rAb-DEK reflect the differential association of DEK with
these substrates and are not due to the differential accessi-
bility to antibody in these complexes, we next probed
directly for the presence of DEK in splicing complexes af-
finity-selected on the dsx substrates (Fig. 4). Splicing com-
plexes were assembled on biotinylated derivatives of the
dsx pre-mRNAs and affinity-selected using streptavidin
agarose. Bound proteins were eluted in high salt and im-
munoblotted first with mAb-104 to confirm the recovery
of splicing complex proteins (Fig. 4 A). In agreement with
our previous results (Li and Blencowe, 1999), low levels of
SR proteins of 30, 40, 55, and 75 kD were detected by
mAb-104 in splicing complexes affinity-selected on the
dsx
 
D
 
E pre-mRNA (Fig. 4 A, lane 3), whereas the levels of
these proteins increased significantly on the dsx(GAA)
 
6
 
pre-mRNA (Fig. 4 A, lane 4). Consistent with the immu-
noprecipitation results in Fig. 3, DEK was detected in
splicing complexes assembled on the dsx(GAA)
 
6
 
 sub-
strate, but not in complexes on the dsx
 
D
 
E pre-mRNA
(Fig. 4 B, compare lanes 3 and 4). The detection of DEK in
association with the dsx(GAA)
 
6
 
 substrate was specific,
since essentially no DEK was selected from a splicing re-
action containing complexes assembled on a dsx(GAA)
 
6
 
pre-mRNA lacking biotinylated residues (Fig. 4 B, lane 2).
The absence of a level of DEK above background in the
affinity-selected dsx
 
D
 
E complexes (Fig. 4 B, lane 3), in
comparison with the low level detected in association with
the dsx
 
D
 
E pre-mRNA by immunoprecipitation (Fig. 3 C,
lane 4), is probably due to the more stringent conditions
used in the affinity-selection assay (300 mM salt) com-
pared with the conditions in the immunoprecipitation as-
say (100 mM salt; see Materials and Methods). Moreover,
the higher levels of SR proteins detected in the affinity-
selected splicing complexes compared with DEK indicates
that they may be more stably associated with the dsx pre-
mRNA (Fig. 4, A and B, compare lanes 1, 3, and 4). These
results confirm that DEK is associated with splicing com-
plexes on the dsx(GAA)
 
6
 
 pre-mRNA and that its associa-
tion with this substrate, like SRm160/300, hTra2beta, and
SR family proteins, is promoted by a purine-rich ESE.
To confirm that SR proteins are required for the stable
association of DEK with pre-mRNA, we next assayed the
ability of rAb-DEK to immunoprecipitate splicing com-
plexes from a cytoplasmic S100 extract (Fig. 5). S100 ex-
tracts contain all of the factors required for splicing, except
SR proteins (Krainer et al., 1990b). These extracts contain
a lower level of DEK than in the same volume of HeLa
nuclear extract (data not shown). Addition of purified SR
family proteins to an S100 reaction resulted in a partial
restoration of splicing activity to the PIP85A pre-mRNA
(Fig. 5, compare lanes 1 and 2). The rAb-DEK antibody
immunoprecipitated a low level of PIP85A pre-mRNA
from an S100 reaction in the absence of SR family proteins
(Fig. 5, lane 4). However, upon addition of purified SR
family proteins, immunoprecipitation of PIP85A pre-
mRNA by rAb-DEK was restored to a level comparable
to that observed in reactions containing total nuclear ex-
tract (Fig. 5, lane 5, and data not shown). This promotion
of immunoprecipitation by SR proteins was not due to an
increase in the level of DEK in the splicing reaction, since
no DEK was detected in the purified SR protein prepara-
tion by immunoblotting with rAb-DEK (Fig. 5 B, lane 3).
Moreover, no difference in the level of DEK was observed
in the S100 splicing reactions after incubation with or with-
out SR proteins (Fig. 5 B, compare lanes 1 and 2). To-
gether with the data in Figs. 3 and 4, these results dem-
onstrate that the association of DEK with pre-mRNA
requires interactions mediated by SR proteins.
 
DEK Associates with SR Proteins In Vivo
 
To investigate whether DEK associates with splicing com-
ponents in vivo, we double-immunolabeled HeLa cells
with rAb-DEK and the anti-SR protein antibody, mAb-
Figure 4. Detection of DEK in affinity-purified splicing com-
plexes. A and B, Biotinylated dsx pre-mRNAs were transcribed
cold and incubated in splicing reactions for 15 min before selec-
tion on streptavidin-agarose. Selections were performed from
splicing reactions incubated with a control, non-biotinylated, dsx
pre-mRNA (dsx(GAA)62bio, lane 2), with a biotinylated dsx
pre-mRNA lacking an ESE (dsxDE1bio, lane 3), and with
a biotinylated dsx pre-mRNA containing a 6xGAA ESE
(dsx(GAA)61bio, lane 4). Proteins recovered from the affinity-
selected splicing complexes were separated on 12% SDS poly-
acrylamide gels and analyzed by immunoblotting with mAb-104
(A) and rAb-DEK (B). Total nuclear extract (lane 1), corre-
sponding to z3% of the amount of extract used in each affinity
selection, was separated as a marker for the eluted SR and DEK
proteins. Sizes of the SR proteins (in kD) detected by mAb-104
are indicated to the right of A. 
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NM4 (Blencowe et al., 1995; Fig. 6, A–F). Similar to many
antibodies that recognize SR proteins, mAb-NM4 specifi-
cally immunolabels nucleoplasmic interchromatin granule
clusters or speckles that are highly enriched in splicing fac-
tors (B and E, and data not shown). In the majority of cells
within a field, rAb-DEK labeling reveals that DEK is spe-
cifically localized in the nucleus in a diffuse-granular pat-
tern that largely, but not completely, excludes nucleoli
(Fig. 6 A). In these cells, DEK overlaps with speckle do-
mains, although it does not appear significantly more con-
centrated in these structures than in other regions of the
nucleoplasm (Fig. 6 C). However, in 
 
z
 
15% of cells within
a field, DEK is significantly more enriched in speckle
structures compared with the surrounding nucleoplasm
(Fig. 6, compare D–F with A–C). The detection of DEK
by immunostaining with rAb-DEK is specific since preim-
mune serum did not immunolabel nuclei (Fornerod et al.,
1996; data not shown). These results indicate that in a sub-
set of cells, DEK is concentrated with SR proteins and
other splicing factors in nuclear speckle structures.
To extend these observations, we next tested whether
the localization of DEK is influenced by the intranuclear
distribution of SR proteins. Recently, we have observed
that SRm160 containing an NH
 
2
 
-terminal Flag epitope
(Flag-SRm160), when overexpressed by transient transfec-
tion, concentrates with endogenous SR proteins in en-
larged speckle structures (Fig. 6 H, and data not shown).
To determine whether the elevated levels of SRm160 in
speckles results in a change in the nucleoplasmic distribu-
tion of DEK, cells transiently transfected with a flag-
SRm160 construct were double-immunolabeled with anti-
flag and rAb-DEK antibodies. Significantly, the presence
of flag-SRm160 in speckles (Fig. 6 H) correlated with an
accumulation of DEK in these structures (Fig. 6 G and I).
This effect was specific since the distribution of DEK was
not altered significantly by the overexpression of a flag-
B23 protein, which concentrates in nucleoli (Fig. 6, compare
J–L). Although every speckle containing flag-SRm160 also
contained an increased level of DEK, in some cases the
size of the speckle domain detected with the antiflag anti-
body was significantly smaller than the size of the corre-
sponding speckle domain detected with rAb-DEK. This may
reflect differences in the relative concentrations of these
proteins between speckles, and/or the differential accessi-
bility of these proteins to antibodies in different speckles.
In either case, the results demonstrate that the distribution
of DEK within nuclei can be specifically influenced by the
localization of SRm160, and that, consistent with the in
vitro interactions with SR proteins, including SRm160/300
described above, DEK probably concentrates in speckles
by associating with one or more of these splicing factors.
 
Depletion of DEK Does Not Prevent
Pre-mRNA Splicing
 
The results so far suggest that DEK could function as a
splicing factor, perhaps by associating with one or more
SR proteins and modulating their activity. To investigate
this possibility, we have prepared nuclear extracts that are
specifically and efficiently depleted of DEK (Fig. 7 A,
compare lanes 1 and 2). Surprisingly, efficient immunode-
pletion of DEK did not affect the level of splicing of sev-
eral pre-mRNAs tested, including the PIP85A (Fig. 7 B,
compare lanes 1 and 2) and the dsx(GAA)
 
6
 
 substrate
(data not shown). Likewise, in contrast to SR proteins and
heteronucleoriboprotein (hnRNP) A1, which promote the
selection of intron proximal and distal 5
 
9
 
 splice sites, re-
spectively (Ge and Manley, 1990; Krainer et al., 1990a; Fu
et al., 1992; Mayeda and Krainer, 1992; Cáceres et al.,
1994), altering the level of DEK by specific immunodeple-
tion in vitro, or by overexpression in vivo, did not signifi-
cantly alter the ratio of intron distal to proximal splice
sites in different pre-mRNAs containing cis-competing
splice sites (data not shown). Whereas it cannot be ex-
cluded that a minor amount of DEK remaining in the im-
munodepleted extract is important for splicing activity, or
that DEK is important for the splicing of specific sub-
strates not assayed, the results so far suggest that DEK
may provide a function that is not directly related to splic-
ing activity.
 
The Association of DEK with the Exon-product RNA 
Requires Prior Splicing
 
The experiments in Fig. 3 reveal that DEK, like SRm160/
300, remains bound preferentially to spliced exons after
splicing. This observation, and the finding that DEK does
not associate efficiently with RNAs that cannot assemble
functional splicing complexes, raises the possibility that its
association with spliced exons requires the prior formation
of a spliceosome. To determine whether the association of
Figure 5. SR proteins promote the association of DEK with pre-
mRNA in S100 splicing reactions. A, Immunoprecipitations with
rAb-DEK were performed from S100 splicing reactions incu-
bated for 1 h containing PIP85A pre-mRNA, with (lanes 2 and 5)
or without (lanes 1, 3, and 4) purified SR family proteins. RNA
recovered after immunoprecipitation (lanes 3–5) and RNA re-
covered directly from a parallel splicing reaction (lanes 1 and 2)
was loaded on a 15% denaturing polyacrylamide urea gel. RNA
loaded in lane 1 represents 25% of the total amount recovered,
whereas RNA loaded in lanes 2–4 from each immunoprecipita-
tion represents 50% of the total amounts recovered. Immunopre-
cipitations were performed with a preimmune serum (lane 3) and
rAb-DEK (lanes 4 and 5). B, Proteins recovered from parallel
S100 splicing reactions as shown in A were separated on a 12%
SDS polyacrylamide gel and immunoblotted with rAb-DEK.
Lanes 1 and 2 correspond to lanes 1 and 2 in A. Lane 3 contains
z3 mg of the SR protein preparation used in A. 
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DEK with spliced exons is facilitated by splicing, we com-
pared the ability of rAb-DEK to immunoprecipitate com-
plexes formed on the exon-product RNA generated by
splicing of PIP85A pre-mRNA, versus complexes formed
on the identical exon-product RNA that has been derived
by transcription from a PIP85A cDNA construct (Fig. 8).
In this assay, splicing reactions were incubated with equal
amounts of PIP85A pre-mRNA and a second RNA that is
not a splicing substrate (a fragment of the HIV-1 Rev-
response element), as an internal control RNA for recov-
ery (Fig. 8, lanes 1 and 3). Although this latter RNA does
not assemble into functional splicing complexes, like the
dsx antisense and dsx
 
D
 
E transcripts, it associates weakly
with SRm160/300 and DEK, permitting its use for moni-
toring immunoprecipitation levels (see below; data not
shown). In a parallel reaction, an equivalent amount of the
internal control RNA was mixed with an exon-product
RNA transcribed from the PIP85 cDNA construct (Fig. 8,
lanes 2 and 4). Both reactions were incubated for one hour
under splicing conditions before immunoprecipitation with
rAb-DEK. Significantly, although a higher level of cDNA-
derived exon-product RNA than spliceosome-derived
exon-product RNA is present in the total splicing reac-
tions (Fig. 8, compare lanes 1 and 3 with lanes 2 and 4),
rAb-DEK only immunoprecipitated efficiently the spli-
ceosome-derived exon-product RNA (compare lanes 7
and 8). This difference was not due to a nonspecific loss of
the cDNA-derived exon-product RNA, since approxi-
mately equivalent levels of the internal control RNA were
immunoprecipitated from both reactions (Fig. 8, compare
lanes 7 and 8). As observed earlier (Fig. 3), in contrast to
the efficient immunoprecipitation of the spliceosome-
derived exon-product complex, rAb-DEK immunoprecip-
itated a significantly lower level of the lariat-product com-
plex of the splicing reaction. This is consistent with the
observation that the majority (80–95%) of exon-product
Figure 6. Association of DEK
with splicing components in
vivo. A–F, HeLa cells were im-
munolabeled with rAb-DEK
(red; A and D) and the anti-SR
protein antibody, mAb-NM4
(green; B and E). In the major-
ity of cells, DEK is diffusely
distributed throughout the nu-
cleoplasm, partially excluding
nucleoli (A). In a subset of cells
(z15%), DEK is detected at
higher levels in interchromatin
granule clusters containing SR
proteins compared with the sur-
rounding nucleoplasm (compare
D and A, and the corresponding
overlays between D and E, and
A and B in F and C, respec-
tively). G–L, Cells were trans-
fected with constructs express-
ing NH2-terminal flag-tagged
SRm160 (flag-SRm160; G–I) or
NH2-terminal flag-tagged B23
(flag-B23; J–L), and the effects
on overexpression of these pro-
teins on the distribution of DEK
were examined. The transfected
cells were double-immunola-
beled with rAb-DEK (red; G
and J) and antiflag (H and K)
antibodies; the sites of overlap
between the signals in G and H,
and J and K, are shown in the
overlays (I and L, respectively).
All of the images were scanned
using a Leica SP confocal micro-
scope. Bar, 5 mm). 
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RNAs generated by splicing are released from the spliceo-
some during in vitro splicing reactions (Le Hir et al., 2000),
and also that a relatively low level of DEK remains bound
to the lariat-product complex after splicing. Preferential
immunoprecipitation of the PIP85A exon-product com-
plex that had been generated by splicing, over the complex
formed on the cDNA-derived exon-product RNA, was
also observed with antibodies to both subunits of the
SRm160/300 splicing coactivator (unpublished observa-
 
tions). This is in agreement with very recent results show-
ing that SRm160 specifically cross-links to spliced exons
dependent on prior splicing (Le Hir et al., 2000; see Dis-
cussion), and also our finding in the present study that
DEK and SRm160/300 associate. Thus, DEK forms a com-
ponent of an exon-product complex, the assembly of
which requires prior splicing. These results suggest that
DEK could function to tag spliced mRNAs as a means to
facilitate one or more postsplicing processes.
 
Discussion
 
We have identified the AML-associated protein DEK as a
factor that interacts in vitro and in vivo with SR proteins
involved in pre-mRNA splicing. DEK associates effi-
ciently with splicing complexes through interactions medi-
ated by SR proteins. Its association with a pre-mRNA is
stimulated by the presence of an ESE that binds to SR
family and SR-related proteins. Moreover, its association
with a pre-mRNA is stimulated by the addition of puri-
fied SR proteins to an SR protein-depleted reaction. Af-
ter splicing, DEK remains associated preferentially with
exon-product complexes. Importantly, this interaction re-
quires prior splicing since DEK does not associate with an
exon-product RNA that has not been generated by splic-
ing. The results indicate that interactions involving DEK
may distinguish a transcript that has been through splicing
from a transcript that has not. Moreover, they suggest that
DEK could function to communicate between splicing and
one or more steps downstream in gene expression.
Increasing evidence indicates that the nuclear history of
a transcript can influence its subsequent metabolism. For
example, it has been demonstrated in many studies that
the presence of an intron is important for efficient gene
expression. These intron-mediated effects have been at-
tributed to influences on mRNA stability, transport and
translation. For example, prior splicing is important for
translation-dependent degradation of mRNA by the non-
sense-mediated decay (NMD) pathway (reviewed by Ma-
quat, 1995, 1996; Hentze and Kulozik, 1999). In a re-
cent study, it was shown that an exon-product RNA
generated by splicing assembles into a complex that is sig-
nificantly larger and more efficiently exported to the cy-
toplasm than the complex formed on the equivalent RNA
synthesized from an intron-less transcript (Luo and Reed,
1999). The presence and location of an intron, whether at
the 5
 
9
 
 or 3
 
9
 
 end of a transcript, can also influence its
translation in the cytoplasm. For example, 
 
Xenopus
 
 ma-
ternal mRNAs transcribed in vivo are normally transla-
tionally masked, but can be relieved from translational
repression by the insertion of an intron at the 5
 
9
 
, but not
at the 39 end, of a transcript (Matsumoto et al., 1998). All
of the above observations indicate the existence of fac-
tors that package an mRNP dependent on its passage
through the spliceosome and that modulate downstream
steps in gene expression. However, the factors that spe-
cifically tag mRNPs dependent on prior splicing are not
known.
hnRNPs such as hnRNP-A1 are candidate factors for in-
fluencing the composition and activity of an mRNP depen-
dent on prior splicing. HnRNP-A1 associates with nascent
pre-mRNA, influences splicing activity, and associates
Figure 7. Immunodepletion of DEK does not prevent pre-
mRNA splicing. A, HeLa nuclear extracts immunodepleted of
DEK with rAb-DEK (lane 2) or mock-depleted with preimmune
serum (lane 1) were separated on a 12% SDS polyacrylamide gel
and immunoblotted with rAb-DEK. Size markers are indicated
in kD. B, Splicing reactions containing rAb-DEK or preimmune-
depleted nuclear extract were incubated with PIP85A pre-
mRNA for 1 h. RNA recovered from the splicing reactions was
separated on a 15% denaturing polyacrylamide gel.
Figure 8. Association of
DEK with spliced exons re-
quires prior splicing. Immu-
noprecipitations were per-
formed with rAb-DEK from
splicing reactions incubated
for 1 h containing PIP85A
pre-mRNA or a PIP85A
exon-product RNA tran-
scribed from a PIP85A
cDNA construct. Both reac-
tions also contained an inter-
nal control RNA for recov-
ery (indicated by a wavy line;
see Results). RNA recov-
ered after immunoprecipita-
tion with rAb-DEK (lanes 7
and 8) or control serum
(lanes 5 and 6) was sepa-
rated, along with the corre-
sponding total samples (lanes 3 and 4, and 1 and 2, respectively),
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with spliced mRNA in the nucleus and cytoplasm; it has
also been detected in association with translationally en-
gaged mRNA (Mayeda and Krainer, 1992; Visa et al.,
1996). However, neither hnRNP-A1 or other hnRNP pro-
teins have been detected in purified spliceosomes and it is
also not known whether their association with mRNPs is
dependent on prior splicing. In contrast, it has been dem-
onstrated that specific SR proteins, including the SRm160/
300 splicing coactivator subunits and ASF/SF2, associate
with splicing complexes through both steps of the splicing
reaction and remain preferentially bound to the exon-
product RNA (Blencowe et al., 1998, 2000; Hanamura et al.,
1998). Moreover, a Chironomas tentans SR family protein,
hrp45, which is related to mammalian ASF/SF2, associates
with intron-containing Balbiani ring transcripts and
remains bound to spliced mRNP until the time the mRNP
is translocated through the nuclear pore complex, upon
which it appears to be released (Alzhanova-Ericsson et al.,
1996). Very recently, Le Hir and colleagues have used an
elegant cross-linking strategy to detect proteins that cross-
link at or near spliced exon junctions, dependent on prior
splicing. In this study, splicing-dependent cross-links were
identified for SRm160, the U5 snRNP protein hPRP8/
p220, and several unidentified proteins (Le Hir et al.,
2000). The results in the present study are consistent with
these findings. In particular, since the association of DEK
with pre-mRNA is promoted by interactions with SR pro-
teins, it is possible that its association with spliced exons is
mediated by SRm160. The results further suggest that in-
teractions involving factors that define mRNP composi-
tion occur as early as the commitment stage of splicing
complex formation, when U1 snRNP and SR family pro-
teins bind to the pre-mRNA and facilitate the association
of factors including SRm160/300 and DEK with the sub-
strate (Blencowe et al., 1998; present study).
The results of the present study, taken together with a
previous finding indicating that DEK associates with the
pets site within the HIV-II promoter (Fu et al., 1997; see
Introduction), reveals an interesting relationship with a
growing number of factors that are associated with both
RNA processing and malignant transformation. For exam-
ple, it has been reported that certain isoforms of the
Wilm’s tumor protein (WT-1) bind to DNA at specific
promoter sequences and concentrate within transcription
factor domains in vivo, whereas other isoforms specifically
associate with splicing components, including snRNPs and
the 65-kD subunit of the U2 snRNP auxiliary factor
(U2AF-65), and concentrate within splicing factor do-
mains in the nucleus (Larsson et al., 1995; Davies et al.,
1998). In another case, the oncoprotein TLS/FUS, which
becomes fused to the CHOP protein in liposarcomas, or to
the ERG protein in a subset of myeloid leukemias, binds
to both DNA and RNA and has recently been identified
as hnRNP-P2, a component of hnRNP complexes (Calvio
et al., 1995). Intriguingly, also similar to DEK, it has been
reported that TLS/FUS interacts with SR protein splicing
factors (Yang et al., 1998). Another factor with dual RNA
and DNA binding properties is the Ets-related transcrip-
tion factor Spi-1/PU.1. This factor, besides its role as a
hematopoietic-specific transcription factor, has been re-
ported to interact with both TLS/FUS and the polypyrimi-
dine tract-binding protein NonO/p54nrb, and to influence
splicing activity (Hallier et al., 1996, 1998). NonO/p54nrb,
which also has the ability to bind to both DNA and RNA,
and a closely related protein, PSF (the polypyrimidine
binding protein–associated splicing factor), were both
identified recently in fusions with the transcription factor
TFE in papillary renal cell carcinomas (Clark et al., 1997).
Thus, all of the RNA processing-associated factors impli-
cated in different human malignancies to date, like DEK,
have associations with transcription components, as well
as with pre-mRNA processing. While the significance of
these similar features is not known, it is tempting to specu-
late that malignancies involving alterations to DEK and
these other proteins could affect functions in transcription,
RNA processing, or perhaps interactions that coordinate
these steps in gene expression (see Introduction). How-
ever, it is also possible that AMLs involving the DEK/
CAN fusion involve an alteration to the normal function
of CAN (Fornerod et al., 1995). Further work will be re-
quired to determine the normal function of DEK and
whether its function is altered by fusion to CAN in AML.
The results in the present study suggest that DEK has a
function in association with pre-mRNA metabolism. In
particular, its association with spliced exons dependent on
prior splicing represents one of the first examples of a pro-
tein with this property. It is possible that this splicing-
dependent association is important for facilitating one or
more steps downstream in gene expression that are influ-
enced by the prior removal of an intron in pre-mRNA.
Thus, based on the previous and present findings, DEK is
a candidate for mediating interactions between transcrip-
tion and pre-mRNA processing, as well as between splic-
ing and one or more subsequent splicing-dependent steps
in the gene expression pathway.
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